These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9088592)

  • 41. Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses.
    Trenk D; Hinder M; Stengele E; Bonn R; Jähnchen E
    J Clin Pharmacol; 2000 Feb; 40(2):168-76. PubMed ID: 10664923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.
    Nordlander R; Walter M
    Eur Heart J; 1994 Jan; 15(1):108-13. PubMed ID: 8174569
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparative study of retard and non-retard forms of isosorbide-5-mononitrate in coronary patients with stable angina pectoris].
    Lupanov VP; Alekseeva IA; Vasil'eva NN; Romasiuk SS; Afanas'eva IuV; Naumov VG
    Klin Med (Mosk); 2000; 78(11):36-8. PubMed ID: 11232528
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A validated gas chromatographic method for the determination of isosorbide-5-mononitrate in human plasma and its application to pharmacokinetic studies.
    Niopas I; Daftsios AC
    Pharmazie; 2001 Jul; 56(7):589-90. PubMed ID: 11487983
    [No Abstract]   [Full Text] [Related]  

  • 45. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study.
    Brun J
    J Int Med Res; 1994; 22(5):266-72. PubMed ID: 7867871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate in ischaemic heart disease.
    Neuhaus R; Johnen R; Vydra L; Solbach C
    Pharmatherapeutica; 1986; 4(8):486-95. PubMed ID: 3086899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
    Geigenberger A; Degen J; Maier-Lenz H
    Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
    Thadani U
    Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isosorbide-5-mononitrate in angina pectoris.
    Poss M; Racicot D; Kiser WR
    Ann Intern Med; 1994 Oct; 121(7):547. PubMed ID: 8093205
    [No Abstract]   [Full Text] [Related]  

  • 50. CGRP mediate the isosorbide-5-mononitrate cardiovascular response in healthy Chinese male volunteers through a XOR-independent pathway.
    Liu Z; Zhang B; Guo X; Chen L; Yi D; Cong J; Guo R
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):325-34. PubMed ID: 25740261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Efficacy and duration of action of isosorbide-5-mononitrate in the treatment of stable angina of effort. Comparison with sustained-release isosorbide dinitrate].
    Lagioia R; Scrutinio D; Mangini SG; De Toma L; Accettura D; De Nicolò M; Saliani P; Preziusi N; Antuofermo F; Rizzon P
    G Ital Cardiol; 1985 Mar; 15(3):299-306. PubMed ID: 4018470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
    Skutta T; Böttcher B; Brandt L
    Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study.
    Nyberg G; Carlens P; Lindström E; Lundman T; Nordlander R; Rehnqvist N; Ulvenstam G; Aberg A; Aström H
    Eur Heart J; 1986 Oct; 7(10):835-42. PubMed ID: 3539613
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
    Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers.
    Hutt V; Bonn R; Fritschi E; Jaeger H
    Arzneimittelforschung; 1995 Feb; 45(2):142-5. PubMed ID: 7710435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
    Döring G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S74-81. PubMed ID: 1282180
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
    Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
    Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
    Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
    Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-ischemic and anti-anginal effects of controlled-release and conventional isosorbide-5-mononitrate in stable angina pectoris.
    Chen YH; Ding PY; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Oct; 61(10):577-83. PubMed ID: 9830234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Abrupt withdrawal of isosorbide 5-mononitrate (Imdur) after long term treatment in stable angina pectoris. A preliminary report.
    Rehnqvist N; Olsson G; Engvall J; Rosenqvist U; Nyberg G; Aberg A; Ulvenstam G; Uusitalo A; Keyriläinen O; Härkönen R
    Drugs; 1987; 33 Suppl 4():118-21. PubMed ID: 2887419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.